NASDAQ:FOLD

Amicus Therapeutics News Headlines

$9.39
-0.36 (-3.69 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.23
$9.71
50-Day Range
$9.19
$10.44
52-Week Range
$8.83
$25.39
Volume2.22 million shs
Average Volume3.70 million shs
Market Capitalization$2.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57

Headlines

Amicus Therapeutics (NASDAQ FOLD) News Headlines Today

SourceHeadline
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by Cantor Fitzgerald to "Overweight"Amicus Therapeutics (NASDAQ:FOLD) Upgraded by Cantor Fitzgerald to "Overweight"
marketbeat.com - April 19 at 8:34 AM
Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call TranscriptAmicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript
fool.com - May 10 at 7:48 PM
Recap: Amicus Therapeutics Q1 EarningsRecap: Amicus Therapeutics Q1 Earnings
benzinga.com - May 10 at 4:20 PM
Amicus Therapeutics (NASDAQ:FOLD) Issues FY 2021 Earnings GuidanceAmicus Therapeutics (NASDAQ:FOLD) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 10 at 9:40 AM
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate UpdatesAmicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
finance.yahoo.com - May 10 at 8:13 AM
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
finance.yahoo.com - May 7 at 9:46 AM
Amicus Therapeutics, Inc. Expected to Earn FY2022 Earnings of ($0.52) Per Share (NASDAQ:FOLD)Amicus Therapeutics, Inc. Expected to Earn FY2022 Earnings of ($0.52) Per Share (NASDAQ:FOLD)
americanbankingnews.com - May 6 at 11:14 AM
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business DevelopmentAmicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
finance.yahoo.com - May 6 at 8:11 AM
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Margaret G. Mcglynn Sells 10,000 SharesAmicus Therapeutics, Inc. (NASDAQ:FOLD) Director Margaret G. Mcglynn Sells 10,000 Shares
americanbankingnews.com - May 5 at 8:49 PM
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley Sells 7,500 SharesAmicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley Sells 7,500 Shares
americanbankingnews.com - May 5 at 8:49 PM
Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Sells $107,978.78 in StockAmicus Therapeutics, Inc. (NASDAQ:FOLD) COO Sells $107,978.78 in Stock
americanbankingnews.com - May 5 at 8:14 PM
Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?
finance.yahoo.com - May 5 at 5:04 PM
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual MeetingAmicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
finance.yahoo.com - May 5 at 12:04 PM
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe DiseaseAmicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
finance.yahoo.com - May 3 at 12:29 PM
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.84Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.84
americanbankingnews.com - May 3 at 11:46 AM
Amicus Therapeutics (FOLD) to Release Quarterly Earnings on MondayAmicus Therapeutics (FOLD) to Release Quarterly Earnings on Monday
americanbankingnews.com - May 3 at 8:18 AM
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe DiseaseAmicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
finance.yahoo.com - May 3 at 7:29 AM
Amicus Therapeutics Recognized as a Great Place to Work® in EuropeAmicus Therapeutics Recognized as a Great Place to Work® in Europe
finance.yahoo.com - April 28 at 8:08 AM
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
finance.yahoo.com - April 26 at 8:25 AM
John F. Crowley Sells 22,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockJohn F. Crowley Sells 22,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock
americanbankingnews.com - April 19 at 7:46 PM
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Cantor FitzgeraldAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Cantor Fitzgerald
americanbankingnews.com - April 19 at 1:12 PM
Is Amicus Therapeutics (NASDAQ:FOLD) Using Debt Sensibly?Is Amicus Therapeutics (NASDAQ:FOLD) Using Debt Sensibly?
finance.yahoo.com - April 18 at 12:12 PM
Reflecting on Amicus Therapeutics (NASDAQ:FOLD) Share Price Returns Over The Last Three YearsReflecting on Amicus Therapeutics' (NASDAQ:FOLD) Share Price Returns Over The Last Three Years
nasdaq.com - April 17 at 5:37 AM
First Week of FOLD June 18th Options TradingFirst Week of FOLD June 18th Options Trading
nasdaq.com - April 16 at 5:36 PM
Why Amicus Therapeutics Stock Is Soaring TodayWhy Amicus Therapeutics Stock Is Soaring Today
fool.com - April 14 at 12:50 PM
Is FOLD Stock A Buy or Sell?Is FOLD Stock A Buy or Sell?
finance.yahoo.com - April 8 at 2:13 PM
Assessing Amicus Therapeutics After Trial ResultsAssessing Amicus Therapeutics After Trial Results
seekingalpha.com - April 5 at 2:23 PM
Amicus Therapeutics (NASDAQ:FOLD) PT Lowered to $13.00Amicus Therapeutics (NASDAQ:FOLD) PT Lowered to $13.00
americanbankingnews.com - March 29 at 8:52 AM
FOLD Apr 2021 22.000 callFOLD Apr 2021 22.000 call
ca.finance.yahoo.com - March 21 at 12:34 PM
FOLD Apr 2021 9.000 putFOLD Apr 2021 9.000 put
ca.finance.yahoo.com - March 21 at 12:34 PM
First Week of May 21st Options Trading For Amicus Therapeutics (FOLD)First Week of May 21st Options Trading For Amicus Therapeutics (FOLD)
nasdaq.com - March 19 at 6:15 PM
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific ConferenceAmicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference
finance.yahoo.com - March 15 at 9:55 AM
Amicus (FOLD) Q4 Earnings Miss Estimates, Sales Beat on GalafoldAmicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold
finance.yahoo.com - March 2 at 6:02 PM
Amicus Therapeutics: Q4 Earnings InsightsAmicus Therapeutics: Q4 Earnings Insights
finance.yahoo.com - March 2 at 3:00 AM
Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call TranscriptAmicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 2 at 3:00 AM
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate UpdatesAmicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
finance.yahoo.com - March 1 at 11:59 AM
Earnings Preview for Amicus TherapeuticsEarnings Preview for Amicus Therapeutics
finance.yahoo.com - February 26 at 1:33 PM
Amicus Therapeutics to Present at Upcoming Investor ConferencesAmicus Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 18 at 8:54 AM
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
finance.yahoo.com - February 17 at 7:11 AM
Amicus Reports Disappointing Tests Results for Pompe Disease DrugAmicus Reports Disappointing Tests Results for Pompe Disease Drug
msn.com - February 12 at 3:11 PM
Amicus Therapeutics Becomes Oversold (FOLD)Amicus Therapeutics Becomes Oversold (FOLD)
nasdaq.com - February 12 at 3:11 PM
Artelo Biosciences leads healthcare gainers; Conformis and Amicus Therapeutics among losersArtelo Biosciences leads healthcare gainers; Conformis and Amicus Therapeutics among losers
seekingalpha.com - February 12 at 1:10 PM
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL StudyAmicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
finance.yahoo.com - February 11 at 6:15 PM
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium(TM) 2021Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium(TM) 2021
marketwatch.com - February 9 at 1:58 PM
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
finance.yahoo.com - February 8 at 7:07 PM
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
finance.yahoo.com - February 8 at 7:07 PM
Amicus shares rise on acquisition speculation from VertexAmicus shares rise on acquisition speculation from Vertex
seekingalpha.com - February 4 at 6:09 PM
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock OptionsImplied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
finance.yahoo.com - January 28 at 2:02 PM
FOLD Feb 2021 31.000 callFOLD Feb 2021 31.000 call
au.finance.yahoo.com - January 28 at 12:01 AM
FOLD Feb 2021 20.000 putFOLD Feb 2021 20.000 put
au.finance.yahoo.com - January 28 at 12:01 AM
FOLD Feb 2021 22.000 callFOLD Feb 2021 22.000 call
au.finance.yahoo.com - January 26 at 11:52 PM
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.